175 related articles for article (PubMed ID: 17726035)
41. Etanercept-associated SLE with lupus nephritis.
Neradová A; Stam F; van den Berg JG; Bax WA
Lupus; 2009 Jun; 18(7):667-8. PubMed ID: 19433471
[No Abstract] [Full Text] [Related]
42. Neurological complications of infliximab.
Tektonidou MG
J Rheumatol; 2007 Jan; 34(1):237; author reply 237-8. PubMed ID: 17216701
[No Abstract] [Full Text] [Related]
43. The tumor necrosis factor-{alpha}-blocking agent infliximab inhibits interleukin 1beta (IL-1beta) and IL-6 gene expression in human osteoblastic cells.
Musacchio E; Valvason C; Botsios C; Ostuni F; Furlan A; Ramonda R; Modesti V; Sartori L; Punzi L
J Rheumatol; 2009 Aug; 36(8):1575-9. PubMed ID: 19567627
[TBL] [Abstract][Full Text] [Related]
44. Effective treatment of refractory pulmonary hemorrhage with monoclonal anti-CD20 antibody (rituximab).
Pinto LF; Candia L; Garcia P; Marín JI; Pachón I; Espinoza LR; Marquez J
Respiration; 2009; 78(1):106-9. PubMed ID: 18799870
[TBL] [Abstract][Full Text] [Related]
45. Focus on adverse events of tumour necrosis factor alpha blockade in juvenile idiopathic arthritis in an open monocentric long-term prospective study of 163 patients.
Gerloni V; Pontikaki I; Gattinara M; Fantini F
Ann Rheum Dis; 2008 Aug; 67(8):1145-52. PubMed ID: 17981916
[TBL] [Abstract][Full Text] [Related]
46. Anti-tumour necrosis factor agents and lipid profile: a class effect?
Garcês SP; Parreira Santos MJ; Vinagre FM; Roque RM; da Silva JA
Ann Rheum Dis; 2008 Jun; 67(6):895-6. PubMed ID: 18474660
[No Abstract] [Full Text] [Related]
47. Rituximab treatment of pulmonary arterial hypertension associated with systemic lupus erythematosus: a case report.
Hennigan S; Channick RN; Silverman GJ
Lupus; 2008 Aug; 17(8):754-6. PubMed ID: 18625655
[TBL] [Abstract][Full Text] [Related]
48. Arthralgia as an adverse event to infliximab: a reactive arthritis or triggering of psoriatic arthritis? Successful management by switching to etanercept.
Moustou AE; Stratigos AJ; Vergou T; Gregoriou S; Georgala S; Danopoulou I
J Eur Acad Dermatol Venereol; 2009 Aug; 23(8):968-9. PubMed ID: 19207660
[No Abstract] [Full Text] [Related]
49. A case of Evans syndrome combined with systemic lupus erythematosus successfully treated with rituximab.
Kittaka K; Dobashi H; Baba N; Iseki K; Kameda T; Susaki K; Kitanaka A; Kubota Y; Ishida T
Scand J Rheumatol; 2008; 37(5):390-3. PubMed ID: 18609263
[TBL] [Abstract][Full Text] [Related]
50. Uveitis and tumour necrosis factor blockade in ankylosing spondylitis.
Coates LC; McGonagle DG; Bennett AN; Emery P; Marzo-Ortega H
Ann Rheum Dis; 2008 May; 67(5):729-30. PubMed ID: 18408116
[No Abstract] [Full Text] [Related]
51. Anti-tumour necrosis factor treatment in patients with refractory systemic vasculitis associated with rheumatoid arthritis.
Puéchal X; Miceli-Richard C; Mejjad O; Lafforgue P; Marcelli C; Solau-Gervais E; Steinfeld S; Villoutreix C; Trèves R; Mariette X; Guillevin L;
Ann Rheum Dis; 2008 Jun; 67(6):880-4. PubMed ID: 18037625
[TBL] [Abstract][Full Text] [Related]
52. Messenger ribonucleic acid expression profile in peripheral blood cells from RA patients following treatment with an anti-TNF-alpha monoclonal antibody, infliximab.
Sekiguchi N; Kawauchi S; Furuya T; Inaba N; Matsuda K; Ando S; Ogasawara M; Aburatani H; Kameda H; Amano K; Abe T; Ito S; Takeuchi T
Rheumatology (Oxford); 2008 Jun; 47(6):780-8. PubMed ID: 18388148
[TBL] [Abstract][Full Text] [Related]
53. Could tumour necrosis factor blockers inhibit the progression of future structural damage in ankylosing spondylitis?
Gaspersic N; Sersa I; Jevtic V; Tomsic M; Praprotnik S
Ann Rheum Dis; 2008 Sep; 67(9):1354. PubMed ID: 18697784
[No Abstract] [Full Text] [Related]
54. A rare and serious cause of pancytopenia in a patient with systemic lupus erythematosus: haemophagocytic lymphohistiocytosis.
Almuwaqqat Z; Roberts JW; Bashtawi Y
BMJ Case Rep; 2018 Sep; 2018():. PubMed ID: 30262544
[No Abstract] [Full Text] [Related]
55. [Hemophagocytic Syndrome: a clinical presentation of systemic lupus erythematosus].
Silva Dda F; Anunciação FA; Arcoverde Jda C; Costa LP; Marques ID; Pinheiro Gda S; Moreira Mdo S
Acta Reumatol Port; 2008; 33(1):91-7. PubMed ID: 18344927
[TBL] [Abstract][Full Text] [Related]
56. Lupus erythematosus complicated by hemophagocytic syndrome.
Romanou V; Hatzinikolaou P; Mavragani KI; Meletis J; Vaiopoulos G
J Clin Rheumatol; 2006 Dec; 12(6):301-3. PubMed ID: 17149063
[TBL] [Abstract][Full Text] [Related]
57. Introduction to special section: biologic agents in the treatment of rheumatic diseases-the first decade.
Yelin E; Katz P
Arthritis Rheum; 2009 May; 61(5):559. PubMed ID: 19405010
[No Abstract] [Full Text] [Related]
58. Drug-induced systemic lupus erythematosus in ankylosing spondylitis associated with infliximab.
Pérez-García C; Maymo J; Lisbona Pérez MP; Almirall Bernabé M; Carbonell Abelló J
Rheumatology (Oxford); 2006 Jan; 45(1):114-6. PubMed ID: 16319096
[No Abstract] [Full Text] [Related]
59. Rituximab in rheumatoid arthritis following anti-TNF-associated tuberculosis.
Burr ML; Malaviya AP; Gaston JH; Carmichael AJ; Ostör AJ
Rheumatology (Oxford); 2008 May; 47(5):738-9. PubMed ID: 18375402
[No Abstract] [Full Text] [Related]
60. Atypical cutaneous tuberculosis in a patient with rheumatoid arthritis treated with infliximab.
Asano Y; Kano Y; Shiohara T
Acta Derm Venereol; 2008; 88(2):183-4. PubMed ID: 18311458
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
